FDA Grants EUA To GlaxoSmithKline’s COVID-19 Monoclonal Antibody

By Kelly Lienhard / May 26, 2021 at 7:17 PM

FDA on Wednesday (May 26) granted emergency use authorization to GlaxoSmithKline’s investigational monoclonal antibody, sotrovimab, for treatment of patients with mild-to-moderate COVID-19.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.